New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
Investor's Business Daily on MSN21h
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...
devdiscourse22h
Disruptions in Health: US Aid Freeze, Rising Measles, and Big Pharma Moves
US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...